HOYA CORPORATION (JP:7741)
:7741
Want to see JP:7741 full AI Analyst Report?
Top Page
HOYA
(7741)
Select Model
Select Model
Rating:83Outperform
Price Target:
¥33,902.00
▲(16.92% Upside)
Action:ReiteratedDate:05/01/26
Strong financial performance (durable profitability, very conservative leverage, and solid cash generation) is the primary driver of the score. Technicals add support with a clear uptrend and positive momentum. Valuation is the main offset, reflecting a moderate premium P/E and low dividend yield.
Positive Factors
Conservative balance sheet
Extremely low leverage and declining debt give HOYA durable financial flexibility and downside protection. This conservative capital structure supports continued investment in capex, R&D or acquisitions, reduces refinancing risk in downturns, and preserves strategic optionality.
Negative Factors
Recent EBIT softness
Operating profit not rising with revenue (EBIT fell from 2025 to 2026) signals rising operating costs or investment that compresses margins. If persistent, this could erode the firm's margin advantage and reduce funds available for reinvestment or shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage and declining debt give HOYA durable financial flexibility and downside protection. This conservative capital structure supports continued investment in capex, R&D or acquisitions, reduces refinancing risk in downturns, and preserves strategic optionality.
Read all positive factors
HOYA (7741) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.40T
Dividend Yield1.01%
Average Volume (3M)1.07M
Price to Earnings (P/E)35.7
Beta (1Y)0.87
Revenue Growth9.44%
EPS Growth28.08%
CountryJP
Employees35,702
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)744.79
Shares Outstanding338,414,300
10 Day Avg. Volume1,057,600
30 Day Avg. Volume1,072,613
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)8.85
Price to Sales (P/S)9.53
P/FCF Ratio40.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥31,390.91Price Target Upside8.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)791.83
Revenue Forecast (FY)¥1.01T
HOYA Business Overview & Revenue Model
Company Description
HOYA Corporation operates as a med-tech company, and a supplier of high-tech and medical products worldwide. The company offers life care products, including eyeglass and contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgica...
How the Company Makes Money
HOYA makes money primarily by manufacturing and selling high-value optical and precision products to both consumers (via eye-care channels) and industrial customers (via electronics and semiconductor supply chains). Key revenue streams include: (1...
HOYA Financial Statement Overview
Summary
Income Statement
87
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
90
Very Positive
| Breakdown | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 947.75B | 866.03B | 762.61B | 723.58B | 661.47B |
| Gross Profit | 748.64B | 693.58B | 606.30B | 567.05B | 511.05B |
| EBITDA | 338.65B | 309.48B | 284.45B | 266.20B | 254.48B |
| Net Income | 253.08B | 202.10B | 181.38B | 168.64B | 164.51B |
Balance Sheet | |||||
| Total Assets | 1.30T | 1.23T | 1.20T | 1.03T | 992.84B |
| Cash, Cash Equivalents and Short-Term Investments | 574.09B | 533.97B | 525.16B | 405.89B | 419.40B |
| Total Debt | 42.24B | 37.28B | 29.24B | 24.58B | 21.60B |
| Total Liabilities | 265.89B | 262.65B | 241.36B | 213.72B | 203.78B |
| Stockholders Equity | 1.02T | 974.02B | 967.76B | 818.32B | 803.85B |
Cash Flow | |||||
| Free Cash Flow | 221.87B | 187.19B | 181.73B | 168.36B | 161.18B |
| Operating Cash Flow | 278.45B | 235.11B | 222.80B | 201.83B | 190.06B |
| Investing Cash Flow | -7.59B | -35.82B | -35.81B | -39.93B | -29.13B |
| Financing Cash Flow | -261.26B | -187.72B | -110.89B | -202.16B | -106.89B |
HOYA Technical Analysis
Positive
28995.00
Price Trends
27921.00
Positive
26052.11
Positive
23153.09
Positive
Market Momentum
570.08
Negative
55.61
Neutral
71.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7741, the sentiment is Positive. The current price of 28995 is above the 20-day moving average (MA) of 28273.03, above the 50-day MA of 27921.00, and above the 200-day MA of 23153.09, indicating a bullish trend. The MACD of 570.08 indicates Negative momentum. The RSI at 55.61 is Neutral, neither overbought nor oversold. The STOCH value of 71.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7741.
HOYA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | ¥9.40T | 35.69 | 25.14% | 1.01% | 9.44% | 28.08% | |
74 Outperform | ¥123.25B | 9.26 | 7.81% | 1.78% | 3.00% | 36.97% | |
73 Outperform | ¥2.94T | 25.64 | 8.98% | 1.22% | 8.34% | 2.79% | |
68 Neutral | ¥861.24B | 24.33 | 11.64% | 0.82% | 13.17% | -1.27% | |
65 Neutral | ¥154.28B | 16.09 | 27.95% | 1.97% | 14.57% | 15.03% | |
59 Neutral | ¥1.73T | 38.56 | 11.34% | 1.01% | 0.18% | 3.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7741
HOYA
27,830.00
9,974.43
55.86%
JP:4543
Terumo
1,989.00
-804.85
-28.81%
JP:7747
Asahi Intecc Co
3,246.00
1,049.11
47.75%
JP:3046
JINS HOLDINGS
6,610.00
-2,027.58
-23.47%
JP:7780
Menicon Co
1,620.00
240.03
17.39%
JP:7733
Olympus
1,571.00
-351.55
-18.29%
HOYA Corporate Events
Hoya Ends ¥100 Billion Buyback and Cancels 1.06% of Its Shares
Apr 30, 2026
Hoya Corporation has completed a share repurchase program and decided to terminate the plan ahead of its original schedule, after buying back 3,576,300 common shares for approximately ¥100 billion via market purchases on the Tokyo Stock Excha...
HOYA Sharply Lifts Annual Dividend Forecast for FY2026
Apr 30, 2026
HOYA Corporation has revised its dividend forecast for the fiscal year ended March 31, 2026, signaling stronger shareholder returns in line with its progressive dividend policy. The company now plans a year-end dividend of 170 yen per share, bring...
HOYA Delivers Strong Quarterly Earnings and Boosts Dividend as Cash Flow Surges
Apr 30, 2026
HOYA reported robust growth for the quarter ended March 31, 2026, with revenue rising 14.5% year-on-year to ¥248.1 billion and profit before tax up 14.6%, while maintaining a strong margin above 31%. Profit attributable to owners grew 5.2%, l...
Hoya Weighs Lowering Investment Unit to Broaden Shareholder Base
Apr 10, 2026
Hoya Corporation has outlined its stance on potentially lowering its investment unit size as part of an effort to broaden its investor base and help invigorate the stock market. The company acknowledges that a lower minimum investment could make i...
Hoya Advances Aggressive Share Buyback as March Repurchases Near ¥36 Billion
Apr 1, 2026
Hoya Corporation has reported progress on its ongoing share buyback program authorized by its board in January 2026, executing market purchases of common stock on the Tokyo Stock Exchange. Between March 1 and March 31, the company repurchased 1,29...
HOYA Delays Spin-Off Date for Japanese Endoscope Business to August 2026
Mar 26, 2026
HOYA Corporation has postponed the planned spin-off of its Japanese endoscope business, which is to be transferred via a simplified absorption-type company split to its wholly owned subsidiary PENTAX Medical Corporation. The effective date, initia...
Hoya Corrects Notice on Intervention in Shareholder Derivative Suit
Mar 2, 2026
Hoya Corporation has issued a corrective notice regarding its previously announced intervention in a shareholder derivative lawsuit involving seven current and former directors and executives. The company clarified that its decision to support the...
Hoya Steps Into Shareholder Lawsuit to Support Current and Former Directors
Mar 2, 2026
Hoya Corporation has decided to intervene in a shareholder derivative lawsuit to support seven current and former directors, including its current president and CEO, after a board review concluded they bear no liability for alleged breaches under ...
Hoya Reports Progress on ¥100 Billion Share Buyback Program
Mar 2, 2026
Hoya Corporation has disclosed the latest progress of its ongoing share buyback program authorized by its board on January 30, 2026, under which it is allowed to repurchase up to 5 million shares for a maximum of ¥100 billion through mid-July...
HOYA Faces Shareholder Derivative Suit Over 2016 Share Buyback
Feb 24, 2026
HOYA has disclosed that it was notified of a shareholder derivative lawsuit filed in the Tokyo District Court against seven current and former directors and executive officers. The suit, brought by an individual shareholder, seeks ¥23,624 mil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.